A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

NCT07283198 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: JSKN033 Injection

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd